newsfilter
← Latest News
GlobeNewswire·

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates

- First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with broad market